SEC Contract Filing

Filing Date: 2020-09-02

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>rare-20200828-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
 <title>EX-10.2</title>
 </head>
 <body>
 <p style="text-align:right;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.08333333333333333in;margin-bottom:0.08333333333333333in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:bold;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.2</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.08333333333333333in;margin-bottom:0.08333333333333333in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><img src="img_2.jpg" alt="img_2.jpg" width="195" height="74"></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.08333333333333333in;margin-bottom:0.5in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">August 28, 2020</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Ms. Shalini Sharp</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Executive Vice President and Chief Financial Officer</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Ultragenyx Pharmaceutical Inc.</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">60 Leveroni Court</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Novato, CA 94949</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.0in;margin-bottom:0.0in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font>&#160;</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.08333333333333333in;margin-bottom:0.16666666666666666in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Re: </font><font style="font-weight:normal;text-decoration:underline;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Amendment No. 1 to Transition Letter Agreement</font><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;"> </font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.3333333333333333in;margin-bottom:0.16666666666666666in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Dear Shalini:</font></p>
 <p style="text-align:left;text-indent:0.0in;margin-left:0.0in;margin-right:0.0in;margin-top:0.08333333333333333in;margin-bottom:0.16666666666666666in;line-height:1.495000;font-family:Times New Roman;font-size:0.1388888888888889in;"><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">On behalf of Ultragenyx Pharmaceutical Inc. (the &#x201c;</font><font style="font-weight:normal;text-decoration:underline;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">&#x201d;), I am pleased to present to you this Amendment No. 1 to the Transition Letter Agreement (this &#x201c;</font><font style="font-weight:normal;text-decoration:underline;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Amendment</font><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which amends the Transition Letter Agreement with you dated March 5, 2020 (the &#x201c;</font><font style="font-weight:normal;text-decoration:underline;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">Transition Letter Agreement</font><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;">&#x201d;) as follows:</font><font style="font-weight:normal;white-space:pre-wrap;color:rgba(0,0,0,1);font-size:12.0pt;font-family:Times New Roman;"> </font></p>
 <p style="text-align:left;text-indent:-0.25in